닥플 플러스
2026 대한조혈모세포이식학회 국제학술대회(ICBMT 2026) - 9월 18일(2일차)
대한조혈모세포이식학회
연수평점 :6점
오프라인
주관
대한조혈모세포이식학회
교육일자
2026-09-18
수강료
200,000원
교육형태
오프라인
등록일시
2026-07-29
교육시간
23시간 20분
연수평점
6점
장소
부산광역시 벡스코
교육종류
내과, 소아청소년과, 진단검사의학과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-09-18 | 08:30~09:00 | Triple Targeting in Myelofibrosis with Momelotinib: An Integrated Therapeutic Approach via JAK1/2 and ACVR1 Inhibition | Seug Yun Yoon(Soonchunhyang University Seoul Hospital ) | - |
| 2026-09-18 | 08:30~09:00 | Immune Reconstitution and Infection Prevention After CAR T-cell and Bispecific Antibody Therapies: The Evolving Role of IVIG | Kwai Han Yoo(Seoul National University College of Medicine) | - |
| 2026-09-18 | 09:00~09:10 | [구연발표]Development of FcRH5 as a therapeutic target in B-cell lymphoma | Jeonghwa Kim(Yonsei University College of Medicine) | - |
| 2026-09-18 | 09:10~09:20 | [구연발표]Longitudinal Whole-Exome Sequencing Revealed Early Clonal Suppression and Delayed Resistance Evolution in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Ibrutinib | Ho Cheol Jang(Chonnam National University Hwasun Hospital) | - |
| 2026-09-18 | 09:20~09:30 | [구연발표]Capturing the Landscape of Electronic Patient-Reported Outcomes During First-Line Lymphoma Therapy: A Multicenter Prospective Study | Kunye Kwak(Korea University College of Medicine) | - |
| 2026-09-18 | 09:30~09:40 | [구연발표]Real-World Outcomes of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (MEITL): a Taiwanese Multicenter Case Series | Chiayu Chen(China Medical University Hospital) | - |
| 2026-09-18 | 09:40~09:50 | [구연발표]Overcoming Poor Prognosis in Post-CAR-T Relapse: Potential Utility of Bispecific Antibodies and Allogeneic Hematopoietic Stem Cell Transplantation as Effective Salvage Strategies | Gi June Min(Seoul St. Marys Hospital, College of Medicine) | - |
| 2026-09-18 | 09:50~10:00 | [구연발표]Prior Bruton Tyrosine Kinase Inhibitor Exposure Is Associated with Inferior Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Mantle Cell Lymphoma | Tong-Yoon Kim(Yeouido St. Marys Hospital, College of Medicine) | - |
| 2026-09-18 | 09:00~09:10 | [구연발표]Risk Stratification For Allogeneic Transplantation In Myelofibrosis: MTSS Versus AlloRisk And The Impact Of Driver Mutation Clearance | Yu-Sung Chang(National Taiwan University Hospital) | - |
| 2026-09-18 | 09:10~09:20 | [구연발표]The Role of Pretransplant Cytoreductive Therapy in Patients with Chronic Myelomonocytic Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation | Jin Zhang(Peking University People) | - |
| 2026-09-18 | 09:20~09:30 | [구연발표]Droplet digital PCR monitoring of JAK2V617F complements donor chimerism after allo-HSCT for myelofibrosis | So Yeon Park(Seoul St. Marys Hospital, College of Medicine, The Catholic University of Korea) | - |
| 2026-09-18 | 09:30~09:40 | [구연발표]Linking Baseline Transcriptomics to Hematopoietic Recovery and Poor Graft Function After Allogeneic Transplantation for Myelofibrosis | Daehun Kwag(Seoul St. Marys Hospital, College of Medicine) | - |
| 2026-09-18 | 09:40~09:50 | [구연발표]Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Myelofibrosis: a Chinese multicenter retrospective study | Yuqian Sun(Institute of Hematology, Peking University) | - |
| 2026-09-18 | 09:50~10:00 | [구연발표]Integrative single-cell genotype-transcriptome analysis reveals mutant transcript and treatment-associated heterogeneity in JAK2 V617F-mutated myeloproliferative neoplasms | Ho Cheol Jang(Chonnam National University Hwasun Hospital) | - |
| 2026-09-18 | 09:00~09:10 | [구연발표]Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65-69 Years | Jung Yeon Lee(Seoul St. Marys Hospital, College of Medicine) | - |
| 2026-09-18 | 09:10~09:20 | [구연발표]One Thousand Autologous Stem Cell Transplants for Multiple Myeloma: Single center, retrospective analysis | Jun Ho Yi(Samsung Medical Center, Sungkyunkwan University School of Medicine) | - |
| 2026-09-18 | 09:20~09:30 | [구연발표]Decoding the role of TANGO1 in myeloma proteostasis and therapeutic vulnerability | Ji Eun Lee(Yonsei University College of Medicine) | - |
| 2026-09-18 | 09:30~09:40 | [구연발표]Long-term follow-up of busulfan plus cyclophosphamide and etoposide versus high-dose melphalan as conditioning in autologous stem cell transplantation for newly diagnosed multiple myeloma | Sungnam Lim(Inje University College of Medicine, Haeundae Paik Hospital) | - |
| 2026-09-18 | 09:40~09:50 | [구연발표]Impact of Acute GVHD and Delayed Hematopoietic Recovery on the Incidence and Clinical Burden of Late Cytomegalovirus Reactivation and Disease After Letermovir Prophylaxis in CBT | Naoki Okada(Kurashiki Central Hospital) | - |
| 2026-09-18 | 09:50~10:00 | [구연발표]Clinical and Basic Studies of Anti-CD25 Monoclonal Antibody for the Prevention of Acute Graft-versus-Host Disease | Yanfei Lu(The First Affiliated Hospital of Guangxi Medical University) | - |
| 2026-09-18 | 09:00~09:10 | [구연발표]Letermovir for Cytomegalovirus Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia Patients: Results of the LETreal study | Yi Xia(Peking University People) | - |
| 2026-09-18 | 09:10~09:20 | [구연발표]Real-World Analysis of Belumosudil in Chronic Graft-versus-Host Disease: Early Progression May Reflect Ruxolitinib Discontinuation-Associated Flare | Jae Ho Yoon(College of Medicine, The Catholic University of Korea) | - |
| 2026-09-18 | 09:20~09:30 | [구연발표]Not All High-Risk Features Are Created Equal: Organ- and Subtype-Specific Determinants of Non-Relapse Mortality in TA-TMA | Seonghan Lee(Seoul St. Marys Hospital, College of Medicine, The Catholic University of Korea) | - |
| 2026-09-18 | 09:30~09:40 | [구연발표]Targeting Steroid-Refractory Chronic GVHD with Reduced-Dose Rituximab Biosimilar (Truxima): A Phase 2 Prospective Study | Suhyeon Lee(St. Vincent Hospital, College of Medicine, The Catholic University of Korea) | - |
| 2026-09-18 | 09:40~09:50 | [구연발표]Letermovir Prophylaxis real world data on Cytomegalovirus Reactivation in Paediatric Haematopoietic Stem Cell Transplantation Recipients: A Single-Centre experience | Krithika Krishnakumar(Apollo Cancer Center) | - |
| 2026-09-18 | 09:50~10:00 | [구연발표]Hyperacute Fatal Transplant-Associated Thrombotic Microangiopathy with Catastrophic Central Nervous System Involvement after HLA-Matched Sibling Transplantation for Severe Aplastic Anemia | Moeko Hino(Chiba University Hospital) | - |
| 2026-09-18 | 10:00~10:10 | 휴식 | - | - |
| 2026-09-18 | 10:10~10:35 | Insights into the Development of Cellular Therapy in China: Current Landscape and Future Directions | Meng Lv(National Clinical Research Center for Hematologic Disease) | - |
| 2026-09-18 | 10:35~11:00 | Chimeric Antigen Receptor T-cell Therapy for Lymphoma in Korea: Current Status, Challenges, and Future Directions | Hyungwoo Cho(University of Ulsan College of Medicine) | - |
| 2026-09-18 | 11:00~11:25 | Unlocking Access of CAR-T therapy in Taiwan: From Dual-Track Regulatory Transformation to National Insurance Breakthroughs | Bor-Sheng Ko(National Taiwan University Cancer Center) | - |
| 2026-09-18 | 11:25~11:50 | Current Status and Challenges of CAR-T Cell Products in Japan: A Regulatory Perspective | Miki Nakamura(Pharmaceuticals and Medical Devices Agency) | - |
| 2026-09-18 | 10:10~10:40 | Leukemic Stem Cells in AML: Mechanisms, Detection, and Therapeutic Targeting | Christopher Park(New York University Grossman School of Medicine) | - |
| 2026-09-18 | 10:40~11:10 | Single-cell Genomics for Predicting and Dissecting Venetoclax Resistance in Monocytic AML | Seongseok Yun(Moffitt Cancer Center & Research Institute) | - |
| 2026-09-18 | 11:10~11:40 | Information-driven Studeis on AML | Sunghyouk Park(College of Pharmacy, Seoul National University) | - |
| 2026-09-18 | 10:10~10:40 | AI-Driven Prediction of Transplant Outcomes | Amin T. Turki(University Hospital Essen) | - |
| 2026-09-18 | 10:40~11:10 | AI-Based Prediction of Early Relapse after CAR-T Therapy | Krishna V. Komanduri(University of California, San Francisco) | - |
| 2026-09-18 | 11:10~11:40 | Clinical Relevance of BM fibrosis in MDS Using Digital Imaging Approaches | Junshik Hong(Seoul National University College of Medicine) | - |
| 2026-09-18 | 10:10~10:40 | Autoimmune Cytopenia and Pure Red Cell Aplasia after HSCT | Kyung Taek Hong(Seoul National University College of Medicine) | - |
| 2026-09-18 | 10:40~11:10 | Best Anti-fungal Prophylaxis and Treatment pre-/post-HSCT | Sung-Yeon Cho(The Catholic University of Korea) | - |
| 2026-09-18 | 11:10~11:40 | Real World Management of CAR T Cell Toxicities-expert Opinion | Stephen A. Grupp(Childrens Hospital of Philadelphia) | - |
| 2026-09-18 | 11:50~12:00 | 휴식 | - | - |
| 2026-09-18 | 12:00~12:40 | From Diagnosis to Transplant: Optimizing the Transplant Bridging Strategy in Secondary AML | Sang-A Kim(Seoul National University College of Medicine) | - |
| 2026-09-18 | 12:00~12:40 | Unlocking the Clinical Value of Early CAR-T Therapy in Multiple Myeloma: Insights from the CARTITUDE-4 Experience | Youngil Koh(Seoul National University College of Medicine) | - |
| 2026-09-18 | 12:00~12:40 | Donor Lymphocyte Infusion after Pediatric Haploidentical HSCT: Indications and Therapeutic Approach | Hee Young Ju(Sungkyunkwan University School of Medicine) | - |
| 2026-09-18 | 12:40~13:00 | 휴식 | - | - |
| 2026-09-18 | 13:00~13:30 | Delegated Manufacturing: Bridging the Gap Between Commercial and Point-of-Care Models for Sustainable Advanced Cellular Therapy Programmes | William Hwang(National Cancer Centre Singapore and Singapore General Hospital) | - |
| 2026-09-18 | 13:30~14:00 | Fine-tuning Signal Strength in CD5 CAR-NK Cells for Targeted T Cell Cancer Therapy | Tae-Don Kim(KRIBB) | - |
| 2026-09-18 | 14:00~14:30 | Multispecific T Cell Engagers, γδ T Cells, and NK Cell–Based Immunotherapy | Kyung-Nam Koh(University of Ulsan College of Medicine) | - |
| 2026-09-18 | 13:00~13:30 | Clinical Translation of Next-Generation Cellular Therapies for Acute Myeloid Leukemia: From Clinical Proof-of-Concept to Hematopoietic Stem Cell–Sparing Immunotherapy | Anthony Daniyan(Memorial Sloan Kettering Cancer Center) | - |
| 2026-09-18 | 13:30~14:00 | Next-generation Switchable CAR-T Platform: Enhancing Precision and Efficacy in Solid Tumors | Kyungho Choi(Seoul National University College of Medicine) | - |
| 2026-09-18 | 14:00~14:30 | Deep B Cell Depletion beyond Hematology: Immune Reset as a New Treatment Paradigm for Autoimmune Diseases | Ricardo Grieshaber-Bouyer(Erlangen-Nürnberg) | - |
| 2026-09-18 | 13:00~13:30 | Ocular Diseases in Hematopoietic Stem Cell Transplantation Patients: Key Indicators for Immediate Recognition | Su-Kyung Jung(National Cancer Center) | - |
| 2026-09-18 | 13:30~14:30 | From Diagnostics to Intervention: Managing Infections in Hematology Patients based on Imaging and Lab Results | Duk Hee Nho(College of Medicine, The Catholic University of Korea) | - |
| 2026-09-18 | 13:00~13:30 | Recent Trends in Conditioning Regimens for Myeloid Malignancies | Ik-Chan Song(Chungnam National University College of Medicine) | - |
| 2026-09-18 | 13:30~14:00 | PTCy as a Universal Platform for GVHD Prophylaxis: Integrating New Standards and Defining the Remaining Role of ATG | Mi Kwon(Gregorio Marañón University General Hospital) | - |
| 2026-09-18 | 14:00~14:30 | Adult Cord Blood Transplantation Program for New Centers: A Practical Institutional Guide | Dong-Yeop Shin(Seoul National University College of Medicine) | - |
| 2026-09-18 | 14:30~14:40 | 휴식 | - | - |
| 2026-09-18 | 14:40~15:20 | Evolution of Cellular Therapies in Management of Lymphoma Patients | Jakub Svoboda(University of Pennsylvania) | - |
| 2026-09-18 | 15:20~16:00 | Management of Mixed Chimerism and Graft Failure in Non-malignant Diseases | Susan E. Prockop(Dana-Farber Cancer Institute) | - |
| 2026-09-18 | 16:00~16:10 | 휴식 | - | - |
| 2026-09-18 | 16:10~16:40 | Poster | - | - |
| 2026-09-18 | 16:40~16:50 | 휴식 | - | - |
| 2026-09-18 | 16:50~17:15 | To Transplant | Mihee Kim(Chonnam National University Medical School) | - |
| 2026-09-18 | 17:15~17:40 | Not to Transplant | Haerim Chung(Yonsei University College of Medicine) | - |
| 2026-09-18 | 17:40~18:05 | Reduced Intensity Conditioning | Jin Kyung Suh(University of Ulsan College of Medicine) | - |
| 2026-09-18 | 18:05~18:30 | Myeloablative Conditioning | Bo Ram Kim(Chonnam National University Hwasun Hospital) | - |
| 2026-09-18 | 16:50~17:15 | EBV-Positive T/NK-Cell and B-Cell Lymphoproliferative Diseases: HSCT as Cure and as Complication | Dae-Ho Choi(Sungkyunkwan University School of Medicine) | - |
| 2026-09-18 | 17:15~17:40 | Clinicopathological Spectrum of EBV-Positive T/NK-Cell Lymphoproliferative Diseases | Yoon Kyung Jeon(Seoul National University College of Medicine) | - |
| 2026-09-18 | 17:40~18:05 | Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcomes from Japanese Nationwide Data | Ayumi Fujimoto(Kameda Medical Center) | - |
| 2026-09-18 | 18:05~18:30 | A Japanese Registry-Based Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis | Haryoon Kim(Keio University) | - |
| 2026-09-18 | 16:50~17:20 | Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in 2026 | Brenda Sandmaier(Fred Hutchinson Cancer Center) | - |
| 2026-09-18 | 17:20~17:50 | Selection of Allogeneic Hematopoietic Progenitor Cell Donors | Brian C. Shaffer(Memorial Sloan Kettering Cancer Center) | - |
| 2026-09-18 | 17:50~18:20 | Optimal Conditioning in Autologous HSCT | Jeong-Ok Lee(Seoul National University College of Medicine) | - |
비고
회원 150,000원, 비회원 200,000원, 기타 80,000원
문의처
담당자
김혜진
연락처
02-516-6581
이메일
bmt@kams.or.kr